NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today reported that its third-quarter revenues declined 2 percent due to the negative impact of acquisitions and foreign currency translation.

The firm's net income, though, inched up around 1 percent as it posted lower costs for the quarter. The results beat analysts' estimates on both the top and bottom line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.